Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALADON neoadjuvant bevacizumab-based therapy in primary breast cancer
2009-013331-37Phase 2Terminated
- Sponsor
- WSG
- Start
- Jun 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab, docetaxel and trastuzumab in breast cancer (2 arms), sponsored by WSG. Primary endpoints: unacceptable toxicity and pathological complete response. Started Jun 2010; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-013331-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013331-37.